Brought to you by

Biovail gets US rights to Solvay's antihypertensive Teveten
25 Apr 2002
Executive Summary
Solvay Pharmaceuticals licensed Toronto-based Biovail US marketing rights to Teveten (eprosartan mesylate) and Teveten HCT (eprosartan mesylate and hydrochlorothiazide combination) for about $94mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com